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Abstract
Our goal was to optimize the radiosensitizing potential of anti-epidermal growth
factor receptor (EGFR) monoclonal antibodies, when given concomitantly with
preoperative radiotherapy in KRAS wild-type locally advanced rectal cancer
(LARC). Based on pre-clinical studies conducted by our group, we designed a
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evaluable for pathology assessment. Although no pCR was observed, seven
patients (41 %) had grade 3 Dworak pathological tumor regression. The regimen
was safe and was associated with 95 % of sphincter-preservation rate. No NRAS,
BRAF, or PI3KCA mutation was found in this study, but one patient (5 %) showed
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Abstract Our goal was to optimize the radiosensitizing po-
tential of anti-epidermal growth factor receptor (EGFR)
monoclonal antibodies, when given concomitantly with pre-
operative radiotherapy in KRAS wild-type locally advanced
rectal cancer (LARC). Based on pre-clinical studies conducted
by our group, we designed a phase II trial in which
panitumumab (6 mg/kg/q2 weeks) was combined with preop-
erative radiotherapy (45 Gy in 25 fractions) to treat cT3-4/N+
KRAS wild-type LARC. The primary endpoint was complete
pathologic response (pCR) (H0=5%, H1=17%, α=0.05, β=
0.2). From 19 enrolled patients, 17 (89 %) were evaluable for
pathology assessment. Although no pCR was observed, seven
patients (41 %) had grade 3 Dworak pathological tumor
regression. The regimen was safe and was associated with
95 % of sphincter-preservation rate. No NRAS, BRAF, or
PI3KCA mutation was found in this study, but one patient
(5 %) showed loss of PTEN expression. The quantification of
plasma EGFR ligands during treatment showed significant
upregulation of plasma TGF-α and EGF following
panitumumab administration (p<0.05). At surgery, patients
with important pathological regression (grade 3 Dworak)
had higher plasma TGF-α (p=0.03) but lower plasma EGF
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(p=0.003) compared to those with grade 0–2 Dworak. Our
study suggests that concomitant panitumumab and preopera-
tive radiotherapy in KRAS wild-type LARC is feasible and
results in some tumor regression. However, pCR rate
remained modest. Given that the primary endpoint of our
study was not reached, we remain unable to recommend the
use of panitumumab as a radiosensitizer in KRAS wild-type
LARC outside a research setting.
Keywords Panitumumab . Locally advanced rectal cancer .
Tumor regression
Introduction
In locally advanced rectal cancer (LARC), preoperative che-
moradiation followed by total mesorectal excision (TME) is
the standard treatment [1–3]. While the addition of chemo-
therapy to preoperative radiotherapy (RT) significantly im-
proves pathologic complete response (pCR) and loco-
regional control (LRC) rates, it does not influence disease-
free survival (DFS) or overall survival (OS) [4, 5]. Novel
approaches are therefore needed to achieve better long-term
outcomes.
In LARC to date, no radiosensitizing agent has surpassed a
5-fluorouracil-based regimen in terms of efficacy. The anti-
epidermal growth factor receptor (EGFR) monoclonal anti-
bodies (moAbs), cetuximab and panitumumab, are approved
by the US Food and Drug Administration for the treatment of
RAS wild-type metastatic colorectal cancer [6, 7]. These anti-
EGFR moAbs have established radiosensitizing properties [8,
9]. Panitumumab is a fully humanized monoclonal antibody
with a lower incidence of infusion hypersensitivity reaction
than cetuximab. Panitumumab can be administered without
premedication using a validated bi-weekly dosing [10].
Several trials, including one by our group, have investigat-
ed EGFR-targeting moAbs in combination with a preopera-
tive chemoradiation regimen in LARC. Early efficacy results
in terms of pCR rate were modest (5 % to 10 %) [11–14].
However, the patient population in these studies was not
selected according to the RAS mutational status. In metastatic
colorectal cancer, the absence of a RAS mutation is a predic-
tive factor of response to anti-EGFR moAbs [15, 16].
It has also been suggested that optimal sequencing of
chemotherapy, radiotherapy, and the EGFR inhibitor might
unlock the full radiosensitizing potential of anti-EGFRmoAbs
[17–21].
Previously in a phase I/II study, we safely combined
cetuximab and capecitabine with preoperative RT in patients
with LARC [11]. However, the study produced a pCR rate of
only 5 %. The first loading dose of cetuximab was given
before the start of chemoradiotherapy. Since tumor cells un-
dergoing mitosis are described as relatively more radio- and
chemosensitive than quiescent ones, the low rate of pCR was
likely caused by a significant decrease in the proliferation of
tumor cells following the first dose of cetuximab, as shown by
our translational research [20]. The low pCR observed in our
earlier trial may have also been caused by a decrease in the
radiosensitizing effects of the chemotherapy and/or cetuximab
when administered with RT using the investigated sequence
[17–21].
To evaluate the impact of radiosensitization using anti-
EGFR moAb in LARC, we conducted a phase II trial of
concomitant panitumumab with preoperative RT in KRAS
wild-type tumors. In the current study, the first dose of
panitumumab was given after the start of RT. With the objec-
tive of identifying predictive biomarkers of response, we also
performed quantification of plasma EGFR ligands during the
course of the study treatment.
Patients and methods
Study objectives
We conducted an open-label, single-arm, multicenter phase II
trial to investigate the activity of panitumumab as a
radiosensitizing agent in KRAS wild-type LARC. The trial
was conducted in accordance with the 1996 Guideline for
Good Clinical Practice, the Declaration of Helsinki, and the
2004 European regulations. Approval from ethics committees
was obtained and all patients signed a written informed
consent.
The primary endpoint was pCR rate in accordance with our
statistical hypothesis. Secondary endpoints included tumor
regression grade according to Dworak et al. [22], negative
circumferential radial margin (CRM) rate, toxicity, LRC rate
at 5 years, and DFS rate at 5 years.
Eligibility
Eligible patients had histologically confirmedKRASwild-type
rectal adenocarcinoma, localized within 15 cm of the anal
margin, cT3–cT4 tumors and/or with nodal involvement (N+
) as determined by endoscopic transrectal ultrasound or pelvic
magnetic resonance imaging, Eastern Cooperative Oncology
Group (ECOG) performance status 0–1, normal bonemarrow,
chemistry, and hepatic and renal functions. Exclusion criteria
included distant metastases, KRAS mutation, and prior expo-
sure to EGFR-targeting therapy.
RAS, BRAF, PI3KCA, and PTEN analyses
Prior to inclusion, eligible patients were screened for the
presence of KRAS codon 12 and 13 mutation. The analysis
was centralized in a certified laboratory (Centre de
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Technologies Moléculaires Appliquées, Université catholique
de Louvain, Belgium). Extracted DNA (EZ1 DNATissue kit,
Qiagen) from formalin-fixed, paraffin-embedded rectal ade-
nocarcinoma tissues was amplified through polymerase chain
reaction (AmpliTaq® Gold DNA Polymerase, Applied
Biosystems).
The forward and reverse KRAS amplification primers were
as follows: KRAS-F, forward, 5′-NNNGGCCTGCTGAAAA
TGACTGAA-3′; KRAS-R, reversed biotinylated primer, 5′-
TTAGCTGTATCGTCAAGGCACTCT-3′; KRAS-2F, for-
ward biotinylated primer, 5′-TGACTGAATATAAACTTG
TGGTAGTTG-3′; and KRAS-2R, reversed primer, 5′-TCGT
CCACAAAATGATTCTGAA-3′.
Samples were run together with a positive control, a
negative control, and a KRAS wild-type control using
the following cycling conditions: 95 °C for 5 min;
40 cycles of 95 °C for 40 s, 58 °C for 40 s, and
72 °C for 80 s; and 72 °C for 7 min.
The next step consisted of immobilizing the PCR products
on streptavidin-coated beads, separating the DNA double
strands, and hybridization of the samples with pyrosequencing
primers to enable the detection of KRAS codon 12 and codon
13 mutations. To do this, 40 μL of streptavidin-sepharose
beads (Streptavidin SepharoseTM High Performance, Qiagen)
and binding buffer (PyroMarkTM, Qiagen) mixture were added
to the plate containing the PCR products for 5 min at room
temperature with constant agitation. Afterwards, the plate was
put into a Vacuum Prep Tool (Qiagen) to prepare the single
strands by denaturation. The beads were then suspended into a
PSQTM96 Plate containing 40μL of pyrosequencing primers
and annealing buffer mixture (PyroMarkTM, Qiagen).
The forward sequencing primers KRAS-PF1 (5′-TGTGGT
AGTTGGAGCTG-3′), KRAS-PF2 (5′-TGTGGTAGTTGG
AGCT-3′), and KRAS-PF3 (5′-TGGTAGTTGGAGCTGGT-
3′) were used to detect codon 12 (GTT and GAT), codon 12
(TGT), and codon 13 (GAC) mutations, respectively.
The reverse sequencing primer, KRAS-2PF (5′-GCACTC
TTGCCTACG-3′), was used to confirm and validate the read-
ing. Primers hybridization was done by heating the PSQ TM
96 Plate to 80 °C for 2 min. Pyrosequencing analyses were
performed in a PSQ96MA pyrosequencer (Qiagen) using the
software provided by the manufacturer (PSQ96MA2.1.1 soft-
ware, Qiagen).
NRAS, BRAF, and PI3KCA mutations as well as PTEN
expression analyses were also centralized and conducted at
another certified laboratory (Institut de Pathologie et de
Génétique, Gosselies, Belgium). Briefly, after standard DNA
extractions followed by genes amplification using the appro-
priate primers by PCR, the NRAS, BRAF, and PI3KCA genes
were sequenced using SNaPshot assays [23]. PTEN protein
expression was studied using standard immunohistochemistry
with rabbit moAb of PTENXPD4.3 as primary antibody (Cell
Signaling Technology, Inc). Details onNRAS, BRAF, PI3KCA,
and PTEN analyses are included in the Supplementary
Materials.
Study design
RT (45 Gy in 25 fractions) was delivered on weekdays (days 1
to 33). To optimize its radiosensitizing activity, panitumumab
(6 mg/kg/q2 weeks, intravenously) was initiated after the start
of RT (day 8) and was administered concomitantly with RTon
days 8, 22, and 36. After the end of RT, a maintenance dose of
panitumumab alone was given on day 50. The conception of
the study design was heavily based upon prior pre-clinical
investigations conducted in our laboratories usingKRASwild-
type human colorectal cancer xenograft models (unpublished
data). Our pre-clinical data suggest that radiosensitization by
anti-EGFR moAb is enhanced when the moAb is introduced
during the course of RT and continued after the completion of
RT. Further details on our laboratory experiments and results
are included in the Supplementary Materials.
Radiotherapy
A dummy run was performed in all participating centers to
standardize the delineation and treatment planning.
Megavoltage equipment was used with 6 MV as minimal
energy. A dose of 45 Gy in 25 fractions (1.8 Gy daily on
weekdays, days 1–33) was delivered. Three-dimensional con-
formal radiotherapywas used for all patients based on a contrast
CT scan of the pelvis. The planning CT was carried out in the
treatment position, with 3- to 5-mm-thick slices. Clinical target
volume (CTV) included the entire mesorectum. Internal iliac
nodes were included up to the venous bifurcation, together with
the presacral nodes (limit S1/S2) [24]. Planning target volume
(PTV) was an isotropic expansion of the CTV (10 mm). Max-
imum, mean, and median dose to the PTV were calculated.
Surgery
TME was performed 6–8 weeks after the end of RT. Postop-
erative chemotherapy was recommended but was left at the
discretion of each investigator. Follow-up was scheduled ev-
ery 3 months for two consecutive years then every 6 months
for a total of five years.
Pathology assessment
Surgical specimens were assessed according to the current
standardized procedure in Belgium [25]. Mesorectum quality
was scored as complete (smooth), nearly complete (mildly
irregular), or incomplete (severely irregular). The surgical
specimen was fixed for 72 h in formalin and sectioned in
parallel cuts of 3 mm to evaluate CRM. CRMwas considered
negative if no tumor cells were visible microscopically at
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<2 mm from the radial margins. Classification of tumors was
performed using the WHO guidelines. Tumors’ histological
differentiation was graded as well, moderately, or poorly
differentiated. Tumor regression was evaluated according to
Dworak’s rectal cancer regression grading [22].
In case of residual macroscopic tumor, standard examina-
tion was performed with three to five sections to investigate
the deepest invasion area. If no macroscopic tumor was ob-
served, the scar area plus a 2-cm margin were sampled to
search for residual cancer structures. If no tumor cells were
visible, three additional levels from each block of the total scar
area were made before a pCR could be confirmed. All lymph
nodes included in the specimen were examined.
Pathology staging was established according to the 5th
edition of the American Joint Committee on Cancer Staging
Manual. Pathology central review was blindly and indepen-
dently performed by two specialized pathologists.
Enzyme-linked immunoabsorbent assay (ELISA)
Plasmawas taken at baseline (day 1), after 1 week of treatment
with RT alone (day 8, 1 h before panitumumab administra-
tion), during the combined RT and panitumumab treatment
(day 22, 1 h after panitumumab administration), during
panitumumab maintenance (day 50, 1 h after panitumumab
administration), and at the time of surgery.
The objective was to study the influence of the study
regimen on EGFR ligands: EGF, transforming growth factor
(TGF)-α, heparin-binding EGF (HB-EGF), betacellulin,
amphiregulin, and epiregulin. Plasma concentrations of these
ligands were quantified using human ELISA Kits (R & D
Systems, UK; Abcam, UK; Gentaur, Belgium) according to
the manufacturer’s instructions.
Statistics
The trial’s sample size was calculated using Simon’s two-step
sequential design with 80 % power for a significance level of
0.05 to reject the null hypothesis of a 5 % pCR rate (based on
the pCR rate obtained with RT alone in the EORTC 22921
trial) and to accept the alternative hypothesis of a 17 % pCR
rate which is averagely produced by concomitant chemora-
diotherapy [3]. An interim analysis was planned after 12
patients had undergone surgery and all the pathology data
had been collected. In accordance with the study protocol,
accrual was not stopped during the interim analysis. If at least
one pCR was observed among the first 12 patients, 30 addi-
tional patients were to be recruited.
Kaplan–Meier curves were used to obtain LRC, DFS, and
OS probabilities. The probability of LRC at 5 years was
calculated from the date of inclusion to the date of confirmed
loco-regional disease relapse. DFS probability was calculated
from the date of inclusion to the date of confirmed disease
progression or death. OS at 5 years was calculated from the
date of inclusion to the date of death. Statistical analysis was
performed using SPSS 16.0.1. Paired and unpaired t tests were
used to compare the means of EGFR ligand concentrations
within and between patient groups, respectively. A two-sided
p value ≤0.05 was considered significant.
Results
Baseline characteristics
From October 2009 to June 2010, 26 eligible patients with
rectal adenocarcinoma were screened for KRAS mutation.
KRAS mutation was detected in five patients (19 %) and
theywere considered as screening failures. Nineteen KRAS
wild-type patients were enrolled in the phase II trial. The
patients’ characteristics are summarized in Table 1.
Toxicity
Toxicities were graded using the National Cancer Institute’s
Common Toxicity Criteria (NCI CTC) version 3.0 (Table 2).
The most frequent grade 1–2 toxicities were asthenia (89 %),
diarrhea (89 %), and acneiform rash (84%). The most common
Table 1 Baseline characteristics
Study population (N=19) Number of patients (%)
Median age, years 63 (range 52–78)
Gender
Male 13 (68 %)
Female 6 (32 %)
ECOG performance status
0 14 (74 %)
1 5 (26 %)
KRAS mutation (exon 2) 0
Baseline TNM staginga
cT2N+ 3 (16 %)
cT3N0 6 (32 %)
cT3N+ 9 (47 %)
cT4N0 0
cT4N+ 1 (5 %)
Distance from anal margin
<5 cm 4 (21 %)
5–10 cm 13 (68 %)
>10 cm 2 (11 %)
ECOG Eastern Cooperative Oncology Group
aAs determined by endoscopic transrectal ultrasound or pelvic magnetic
resonance imaging (taking into account the poorest TNM stage when
both investigations were performed)
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grade 3 toxicity was leucopenia (26 %). Four grade 4 adverse
events were reported: sepsis (n=1), pulmonary embolism (n=
1), hypomagnesemia (n=1), and hypophosphatemia (n=1).
The median relative dose intensity of panitumumab and
radiotherapy was 99.4 % (95 % confidence interval=91.3–
100) and 94.3 % (95 % confidence interval=92.8–99.2 %),
respectively.
Efficacy
Pathology results
The pathology results are summarized in Table 3. Two pa-
tients (10 %) were not evaluable for rectal cancer pathology
assessment because their tumors were confirmed to be sig-
moid adenocarcinomas (>15 cm from the anal margin). Six
patients (35 %) showed tumor downstaging compared to
baseline cTNM. The mesorectum excision was considered
incomplete in two patients (12 %). Negative CRM was found
Table 2 Toxicity
Adverse events NCI CTC version 3.0 grade
(N=19)
N (%) 1 2 3 4
Hematologic
Anemia 8 (42) 1 (5) 1 (5) 0
Leucopenia 0 4 (21) 5 (26) 0
Thrombopenia 3 (16) 0 0 0
Gastrointestinal
Anorexia 3 (16) 1 (5) 1 (5) 0
Constipation 2 (10) 5 (26) 0 0
Diarrhea 15 (79) 2 (10) 0 0
Low gastrointestinal bleeding 2 (10) 4 (21) 0 0
Stomatitis 3 (16) 1 (5) 0 0
Proctitis 2 (10) 5 (26) 0 0
Nausea 3 (16) 0 0 0
Vomiting 1 (5) 0 0 0
Other (tenesma) 1 (5) 4 (21) 0 0
Nail toxicity 0 1 (5) 1 (5) 0
Skin toxicity
Acneiform rash 9 (47) 7 (37) 1 (5) 0
Dermatitis 0 0 1 (5) 0
Dry skin 12 (63) 4 (21) 0 0
Erythema 7 (37) 4 (21) 0 0
Pruritis 5 (26) 3 (16) 0 0
Other (fissures, local skin infection) 3 (16) 1 (5) 0 0
Other
Asthenia 14 (74) 3 (16) 1 (5) 0
Cardiac arrhythmia 1 (5) 0 1 (5) 0
Creatinine increased 1 (5) 2 (10) 0 0
Elevated ASAT or ALAT 4 (21) 0 0 0
Elevated GGT 1 (5) 0 3 (16) 0
Hypocalcemia 6 (31) 1 (5) 0 0
Hypokalemia 1 (5) 0 1 (5) 0
Hypomagnesemia 3 (16) 3 (16) 0 1 (5)
Hypophosphatemia 5 (26) 2 (10) 3 (16) 1 (5)
Hypotension 1 (5) 1 (5) 0 0
Infection 0 0 3 (16) 1 (5)
Local–regional pain (anal, perineal) 4 (21) 8 (42) 0 0
Thromboembolic event 0 0 0 1 (5)
Weight loss 4 (21) 3 (16) 0 0
NCI CTC National Cancer Institute’s Common Toxicity Criteria, AST
aspartate aminotransferase, ALAT alanine aminotransferase, GGT
gamma-glutamyl transpeptidase
Table 3 Pathology central review
Pathology outcomes (N=17)a
Histology differentiation
Well differentiated 1 (6 %)
Moderately differentiated 15 (88 %)
Poorly differentiated 1 (6 %)
Circumferential radial margin
>10 mm 9 (53 %)
2–10 mm 4 (23 %)
<2 mm 3 (18 %)
<1 mm 0
Not evaluable 1 (6 %)
ypTN stage
ypT1N0 3 (18 %)
ypT1N1 0
ypT1N2 0
ypT2N0 3 (18 %)
ypT2N1 0
ypT2N2 0
ypT3N0 7 (41 %)
ypT3N1 3 (18 %)
ypT3N2 1 (6 %)
Dworak tumor regression grade
4 0
3 7 (41 %)
2 7 (41 %)
1 3 (18 %)
0 0
Oncogene mutation status
NRAS (exon 2) 0
BRAF (V600E) 0
PI3KCA (exons 9 and 20) 0
PTEN expression 16 (94 %)
a Two patients were excluded from the pathology efficacy evaluation
because their tumors were sigmoid adenocarcinomas
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in 13 patients (76 %). Dworak grade 3, 2, and 1 was found in
seven (41 %), seven (41 %), and three (18 %) patients,
respectively. No pCR (grade 4 Dworak) was observed.
Follow-up
The median time interval from the completion of RT to
surgery was 6 weeks (range 5–8 weeks). TME with
colo-anal anastomosis was performed in 18 patients
(95 %). One patient (5 %) underwent an abdomino-
perineal resection. Postoperative serious adverse events
included pulmonary embolism (n=1), systemic infection
(n=1), and delayed resumption of bowel motility (n=1).
Nine patients (47 %) received postoperative 5-
fluorouracil-based chemotherapy. With a median
follow-up of 53 months (range 14–60 months), two
patients (10 %) had developed distant metastases, one
patient (5 %) had confirmed loco-regional relapse, and
one patient (5 %) had simultaneous loco-regional and
distant relapses. In addition, three patients (16 %) died
due to disease progression and another (5 %) from a
non-cancerous cause. Local-control, disease-free, and
overall survival probabilities according to Kaplan–Meier
are shown in Fig. 1.
EGFR ligands expression
ELISA results are summarized in Fig. 2. Among the quanti-
fied EGFR ligands, only plasma EGF and TGF-α showed
significant variations from baseline.
For plasma EGF, no significant change from baseline
was observed after treatment with RT alone (day 8) or
during concomitant RT and panitumumab (day 22).
However, panitumumab treatment after the end of RT
(day 50) triggered a significant rise in plasma EGF
concentration (p<0.05) (Fig. 2a). Similarly, a significant
increase in mean plasma TGF-α in relation to
panitumumab administration (p<0.001) was also ob-
served (Fig. 2b), suggesting that the changes in the
expression of EGFR ligands during the study treatment
were induced rather by panitumumab than by RT or
concomitant RT and panitumumab.
Interestingly, patients with Dworak grade 3 histolog-
ical regression tended to have a lower plasma EGF
concentration during treatment compared to patients
with poor histological response (Dworak grade 0–2).
However, this difference only reached statistical signif-
icance (p=0.003) at the time of surgery (Fig. 2c). Con-
versely, patients with Dworak grade 3 had a higher
plasma TGF-α at the time of surgery compared to those
with Dworak grade 0–2 (p=0.03) (Fig. 2d).
No significant change from baseline was found during
treatment for the other EGFR ligands (data not shown).
Discussion
EGFR-targeting moAbs have proven their efficacy in patients
with metastatic colorectal cancer [6, 7, 15, 16]. However, their
potential to improve outcome in the preoperative setting of
LARC remains uncertain [11–14]. Our work set out to chal-
lenge key hypotheses that may explain the lack of improve-
ment in the pCR rate obtained when anti-EGFR moAbs are
added to preoperative chemoradiation in rectal cancer. We and
others have previously highlighted the importance of optimal
treatment sequencing when combining an EGFR inhibitor
with chemoradiation [17–21]. In our study, the bimodality
approach of panitumumab and RT was chosen for two rea-
sons. First, it enabled us to evaluate the full capacity of
panitumumab as a radiosensitizer in KRAS wild-type LARC,
Fig. 1 Local-control, disease-free, and overall survival probabilities at
5 years
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without the interference of chemotherapy. We intended to
investigate whether the addition of anti-EGFR moAb to RT
would allow us to achieve a pCR rate of 17 %, which is in the
range of pCR obtained with standard chemoradiotherapy [3].
Second, we aimed to test the hypothesis, as described by
others [26] and confirmed by our pre-clinical results (see
Supplementary Materials), that radiosensitization with anti-
EGFR moAbs could be improved when anti-EGFR moAb is
initiated during RT and continued after the end of RT. How-
ever, even with an optimized study design, our trial closed
prematurely as it failed to achieve its primary endpoint.
Currently, there is no validated predictive biomarker
for anti-EGFR-based chemoradiation regimen in LARC.
The predictive value of RAS mutation, an established
molecular marker in metastatic colorectal cancer, re-
mains conflicting in LARC [27–29]. Some promising
markers in the metastatic setting, NRAS, BRAF, and
PIK3CA mutations, have yet to prove their significance
in the neoadjuvant setting [16, 30, 31]. In this study,
none of these mutations were found but one patient
(5 %) with a poor clinical outcome showed a loss of
PTEN expression in the tumor tissue.
Another potential biomarker in LARC is EGFR ligand
expression. In our previous trial, we found that cetuximab
increased plasma TGF-α concentration and that the increase
was significantly correlated with tumor downstaging [20].
Similarly, our present data showed that plasma TGF-α was
significantly increased with panitumumab. Plasma EGF dur-
ing panitumumab monotherapy was also upregulated; how-
ever, no significant change from baseline was observed during
treatment with RT alone or during concomitant RT and
panitumumab.
At the time of surgery, we found higher plasma TGF-α
but lower plasma EGF concentrations in responsive pa-
tients with grade 3 Dworak compared to those with grade
0–2 Dworak. TGF-α overexpression has been associated
with biological resistance to cetuximab and panitumumab
in colorectal cancer cells. Some investigators have sug-
gested that paracrine secretion of TGF-α plays a protective
role against EGFR blocking in the surviving cancer cells.
This paracrine-derived defense mechanism was not found
with other EGFR ligands except for amphiregulin [32].
Other pre–clinical evidence showed that increased TGF-α
concentration might trigger an EGFR–MET interaction.
TGF-α could promote resistance to anti-EGFR monoclonal
antibody by subsequently inducing MET phosphorylation
and activating its downstream signaling pathways [33]. In
patients with significant response to panitumumab, an in-
crease in plasma TGF-α and consequently an active bio-
logical defense mechanism may simply be an indication of
a highly effective EGFR blockage by the monoclonal an-
tibody. These findings and hypotheses should be
interpreted with caution as it is based on a limited number
of patients.
Fig. 2 Plasma EGF and TGF-α. RT radiotherapy, PAN panitumumab,
SEM standard error mean, TRG Dworak’s tumor regression grade. a, b
The impact of the study treatment on plasma EGF and TGF-α concen-
trations (N=17). c, d Plasma EGF and TGF-α concentrations according
to pathological tumor regression. Dworak grade 0 to 2 (N=10) was
considered as minimal regression. Dworak grade 3 (N=7) was considered
as good regression
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EGFR-targeting moAbs appear to have limited efficacy as
radiosensitizers in rectal cancer, but the reason for this remains
unclear. Glynne-Jones et al. [19] pointed out that the total
radiation dose used in LARC (45–50.4 Gy) is below the
curative threshold. In this setting, and unlike cytotoxic che-
motherapy, anti-EGFR moAbs may not induce sufficient cell
kill, particularly in the presence of subpopulations of
radioresistant tumor cells, thus decreasing the probability of
achieving pCR. Intrinsic cellular radiosensitivity, accelerated
repopulation, hypoxia, and the activation of other growth
factor receptors may also have contributed to our study regi-
men’s lack of activity [34–36].
There are limitations but also encouraging facts in our
study. First, this was a small and non-randomized phase II
trial. Second, chemotherapy was not given concomitantly
with RT. The EORTC 22921 rectal cancer trial showed that
local recurrences were reduced to the same extent with either
postoperative chemotherapy or preoperative chemoradiother-
apy [3]. Postoperative chemotherapy was given to 47 % of
patients in this study (data not shown). Even so, LRC, DFS,
and OS rates fell within the expected ranges for this popula-
tion. Furthermore, the addition of concurrent chemotherapy to
RT has never been shown to improve OS in rectal cancer [4].
While several studies have questioned the relevancy of pCR
as an endpoint for neoadjuvant LARC trials, other groups
found that patients with pCR have a favorable prognosis
[37, 38]. pCR has been correlated with low loco-regional
recurrence rates, lower risk of lymph-node metastases,
and 5-year survival rates greater than 95 % in several
studies [39]. Moreover, the emergence of the “wait and
watch” non-operative approach in LARC is based on the
hypothesis that patients with radio(chemo)sensitive tumors
who will achieve pCR could be spared from surgery [39].
A recent report also showed that patients with “near-pCR”
type of response had poor prognosis with DFS and OS
rates comparable to the non-responsive patients [40]. To-
gether, these facts support the use of pCR as an endpoint
for LARC trials.
Concomitant panitumumab and radiotherapy in this study
was feasible, as reflected by the median dose intensity of both
regimen, and was associated with acceptable rate of perioper-
ative complications. In addition, we obtained a high rate of
colorectal anastomosis in our study (95 %) despite having
21 % of patients with tumors located at less than 5 cm from
the anal margin.
A randomized phase II trial, SAKK 41/07, reported that a
high proportion of KRAS wild-type patients achieved pCR and
near-pCR when treated with panitumumab and capecitabine-
based chemoradiation [28]. Despite their interesting findings,
the pCR rate alone, without taking into account near-pCR
response rate, fell within the range of what is expected with a
5-fluorouracil- or capecitabine-based chemoradiation regimen.
Due to the overlapping confidence intervals between the
investigational and control arms, the contribution of
panitumumab to pCR or pathologic downstaging requires fur-
ther investigation.
In summary, our work suggests that preoperative
radiosensitization using panitumumab in KRAS wild-type
LARC is associated with pathological tumor regression but
without any improvement in the overall pCR rate. Given that
pCR was selected as the primary endpoint of our study, we
remain unable to recommend the use of panitumumab as a
radiosensitizer in KRAS wild-type LARC outside a research
setting.
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